Novel thrombopoietic agents: preliminary activity, potential benefit.
Bussel
James B
JB
Weill Cornell Medical College, Division of Pediatric Hematology, Payson 609, 525 E. 68th Street, New York, NY 10021, USA. jbussel@med.cornell.edu
D000970:Antineoplastic Agents / Q000009:adverse effects; D002352:Carrier Proteins / Q000627:therapeutic use; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D006801:Humans; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D011961:Receptors, Fc / Q000627:therapeutic use; D053628:Receptors, Thrombopoietin / Q000819:agonists* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D034061:Thrombopoiesis / Q000187:drug effects*; D013926:Thrombopoietin
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D003115:Colony-Stimulating Factors; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim